Dr Reddy’s receives EU nod for AVT03 biosimilar denosumab
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
This is the first and only subcutaneous immune checkpoint inhibitor available in Europe
Subscribe To Our Newsletter & Stay Updated